Resiquimod
Topical | |
ATC code |
|
---|---|
Legal status | |
Legal status |
|
Identifiers | |
| |
JSmol) | |
| |
| |
(what is this?) (verify) |
Resiquimod (R-848) is a drug that acts as an immune response modifier, and has
opioid growth factor receptor.[9]
On 28 April 2016, orphan designation (EU/3/16/1653) was granted by the European Commission to Galderma R&D, France for resiquimod to be used in the treatment of cutaneous T-cell lymphoma.[10]
See also
References
- ^ Patents #5, 939, 090 and 6, 365, 166
- S2CID 205257237.
- PMID 15498602.
- PMID 18039918.
- PMID 26228486.
- S2CID 30401602.
- PMID 31015631.
- PMID 19249118.
- S2CID 35164284.
- ^ Committee for Orphan Medicinal Products (27 May 2016). "Resiquimod for the treatment of cutaneous T-cell lymphoma" (PDF). Public summary of opinion on orphan designation. European Medicines Agency.